Julius Clinical
13
2
6
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
20%
1 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Serranator POINT FORCE Registry
Role: collaborator
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
Role: collaborator
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults and Adolescents
Role: collaborator
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children
Role: collaborator
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Role: collaborator
Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children
Role: collaborator
The KHENERGYC Study
Role: collaborator
Global Research Initiative for Patients Screening on MASH
Role: lead
The KHENEREXT Study
Role: collaborator
Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)
Role: collaborator
Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage
Role: collaborator
The KHENERGYZE Study
Role: collaborator
Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
Role: collaborator
All 13 trials loaded